The U.S. Food and Drug Administration today cleared for marketing the Xpert Carba-R Assay, an infection control aid that tests patient specimens to detect specific genetic markers associated with bacteria that are resistant to Carbapenem antibiotics. Carbapenem antibiotics are widely used in hospitals to treat severe infections. These resistant organisms are commonly referred to as Carbapenem-resistant Enterobacteriaceae, or CRE, and have been reported in almost all states within the U.S.
OSAP Disclaimer | Please notify our webmaster of any problems with this website. OSAP thanks its Super Sponsors for their support in 2017. Sponsorship does not imply endorsement by OSAP of a company's products or services.